Clinical Trials Logo

Early Stage Parkinson's Disease clinical trials

View clinical trials related to Early Stage Parkinson's Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00623324 Completed - Clinical trials for Early Stage Parkinson's Disease

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are able to wash off dopamine agonists for 14 days prior to baseline. Efficacy will be assessed using the UPDRS questionnaire including part 3 of the UPDRS (Motor). their level of sleepiness on a standardized rating scale (Epworth Sleepiness Scale) and their level of nausea daily. Safety endpoints will include adverse events (AEs), clinical laboratory data, vital signs (blood pressure, orthostatic blood pressure and heart rate), ECGs, physical examinations and self rated scales.

NCT ID: NCT00599196 Completed - Clinical trials for Early Stage Parkinson's Disease

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease

NCT ID: NCT00594165 Completed - Clinical trials for Early-Stage Parkinson's Disease

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

SP512OL
Start date: June 2002
Phase: Phase 3
Study type: Interventional

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.

NCT ID: NCT00335374 Completed - Clinical trials for Early Stage Parkinson's Disease

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Start date: August 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

NCT ID: NCT00332917 Completed - Clinical trials for Early Stage Parkinson's Disease

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial

NCT ID: NCT00269516 Completed - Clinical trials for Early Stage Parkinson's Disease

SLV308 for Treatment of Patients With Early Parkinson's Disease

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.